-
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
-
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
